Clinical trials: Hypertension and Hyperlipidemia
Insulin Resistance, Obesity
Pilot Study of GLY-LOW Supplementation in Postmenopausal Women With Obesity
A combination of generally regarded as safe (GRAS) compounds named GLY-LOW, which included: alpha lipoic acid, pyridoxamine, nicotinamide, piperine and thiamine, were examined in pre-clinical experiments.
- Conditions
- Insulin Resistance, Obesity, Cardiovascular Diseases, Cognitive Impairment
- Trial name
- NCT06242535
- Testing
- GLY-LOW
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Hoskinson Health and Wellness Clinic
Hypertension, Hyperlipidemias
Pharmacokinetic Drug-drug Interaction of CKD-330 and D086
The purpose of the study is examining and comparing the pharmacokinetic drug interaction and safety of both single administration and combination administration of CKD-330 and D086 to healthy male subjects
- Trial name
- NCT03017950
- Testing
- CKD-330, D086, CKD-330 + D086
- Where
- South Korea
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Coronary Artery Disease, Hypercholesterolemia, Hypertension
Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World Setting
The study is to verify atorvastatin effectiveness and safety in Chinese population, and explore the optimal atorvastatin regimens in high-to-moderate risk for ASCVD。
- Trial name
- ATTENTION (NCT02565615)
- Testing
- No intervention
- Where
- 54 sites in China
- Volunteers
- 5,115 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Type 2 Diabetes Mellitus
Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension
Primary Objective: To evaluate the effect of irbesartan/atorvastatin fixed-dose combination comparing to each irbesartan and atorvastatin on flow mediated dilation change in type 2 diabetic patients diagnosed with hyperlipidemia…
- Trial name
- NCT02842359
- Testing
- Irbesartan/atorvastatin fixed dose combination, Irbesartan SR47436, Atorvastatin
- Where
- South Korea
- Volunteers
- 11 people
- Sponsor
- Sanofi
Hypercholesterolemia, Hypertension
Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine
The purpose of this study is to evaluate the efficacy and safety of co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine in patients with primary hypercholesterolemia and essential hypertension.
- Trial name
- NCT04158076
- Testing
- Ezetimibe/Rosuvastatin, Telmisartan, Telmisartan/Amlodipine 80 Mg-5 Mg ORAL TABLET
- Where
- South Korea
- Volunteers
- 131 people
- Sponsor
- Addpharma Inc.
Hypertension, Hyperlipidemia
Study to Evaluate the Safety and Efficacy of CJ-30061 in Hypertensive Patients With Hyperlipidemia
To evaluate the safety and efficacy of CJ-30061 compared with amlodipine/valsartan combination therapy and valsartan/atorvastatin combination therapy in hypertensive patients with hyperlipidemia
- Trial name
- NCT03639480
- Testing
- Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg, Amlodipine 10mg+Valsartan 160mg, Valsartan 160mg+Atorvastatin 40mg
- Where
- South Korea
- Volunteers
- 180 people
- Sponsor
- HK inno.N Corporation
Hypertension, Hyperlipidemia
Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels
The purpose of the study is to measure the effect of the amlodipine/atorvastatin combination pill in reducing both elevated blood pressure and cholesterol levels to levels suggested by guidelines
- Trial name
- GEMINI-AALA (NCT00143234)
- Testing
- Amlodipine/atorvastatin single pill
- Where
- 118 sites in Argentina, Australia and 25 more
- Volunteers
- 1,825 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Cardiovascular Diseases, Hyperlipidemias
Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia Control
Fimasartan and Rosuvastatin for hypertension and dyslipidemia control
- Trial name
- FIMARO (NCT02913794)
- Where
- South Korea
- Volunteers
- 541 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension, Hypercholesterolemia
A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia
The purpose of this study is to provide data on the dose response of simvastatin in lowering LDL-C when it is co-administered with valsartan in patients with both essential hypertension and hypercholesterolemia.
- Trial name
- NCT00254475
- Testing
- simvastatin, valsartan
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 871 people
- Sponsor
- Novartis
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Truway Diagnostic Tools in Primary Care
This study evaluates the effectiveness of Truway Health-sourced portable diagnostic devices, including ultrasound and blood glucose monitors, in early detection of chronic conditions in outpatient primary care settings.
- Conditions
- Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Hypertension, Cardiovascular Disease Acute
- Trial name
- TruDxPC (NCT07209527)
- Testing
- Truway Portable Ultrasound Device, Truway Blood Glucose Monitor, Standard Oral Hypoglycemic Agent
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Truway Health, Inc.
Obesity, Diabetes Mellitus, Type 2
A Study of the Safety and Efficacy of Topiramate in the Treatment of Obese, Type 2 Diabetes Patients on a Controlled Diet
The purpose of this study is to determine the efficacy and safety of topiramate compared with placebo in obese, Type 2 diabetic patients on a controlled diet.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
- Trial name
- NCT00231530
- Testing
- topiramate
- Volunteers
- 541 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hypertension, Hyperlipidemia
Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan
The objective of this study is to compare pharmacokinetics after single oral administration of rosuvastatin and valsartan each separately versus coadministration of rosuvastatin and valsartan in healthy male volunteers.
- Trial name
- NCT01609907
- Testing
- Rosuvastatin+Valsartan (Sequence 1), Rosuvastatin+Valsartan (Sequence 2), Rosuvastatin+Valsartan (Sequence 3)
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Hypertension, Hypercholesterolemia
Clinical Trial to Evaluate the Efficacy and Safety of DP-R212
The purpose of this study is to determine superiority of DP-R212 comparing to each monotherapy in patient with hypertension and primary hypercholesterolemia.
- Trial name
- NCT02955368
- Testing
- DP-R212, C1-R212, C2-R212
- Sponsor
- Alvogen Korea
Hypertension, Hyperlipidemia
A Study to Evaluate Pharmacokinetics and Potential Drug Interactions of a Fixed-dose Combination Tablet, HL-040XC, in Healthy Male Subjects
The objective of this study is: To evaluate the pharmacokinetics and safety of an experimental combination tablet containing 20 mg atorvastatin and 50 mg losartan potassium when administered orally as a single dose to healthy…
- Trial name
- NCT01806324
- Testing
- HL040XC, Losartan + Atorvastatin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- HanAll BioPharma Co., Ltd.
Hyperlipidemia, Hypertension
Pharmacokinetic Study of Livalo® Fixed Combination Drug in Healthy Subjects
The purpose of this study is to compare pharmacokinetics between Pitavastatin and Valsartan co-administration and Livalo fixed combination drug in healthy male subjects.
- Trial name
- NCT01406431
- Testing
- Pitavastatin, Valsartan, Livalo® fixed combination drug
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- JW Pharmaceutical
Hypertension, Hyperlipidemia
PK Study of YH22189 FDC Compared to Combination of Telmisartan/Amlodipine and Rosuvastatin
This is a Randomized, open-label, single-dose, 3-treatment, 3-period, 3-sequence crossover design.
- Trial name
- NCT02608242
- Testing
- YH22189, Twynsta 80/10mg, Crestor 20mg
- Where
- South Korea
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Hypertension, Hyperlipidemia
Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia
To identify efficacy and safety of Telmisartan/Rosuvastatin co-administration in hyperlipidemia control in hypertensive patients with hyperlipidemia compared to each monotherapy.
- Trial name
- NCT02087540
- Testing
- Telmisartan 80mg, Rosuvastatin 20mg, Rosuvastatin 10mg
- Where
- South Korea
- Volunteers
- 310 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Hypertension, Hyperlipidemia
A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C
To evaluate the pharmacokinetic interactions of AD-231A, AD-231B, and AD-231C in healthy adult volunteers.
- Trial name
- NCT07312773
- Testing
- Treatment A(AD-231A), Treatment B(AD-231B+AD-231C), Treatment C(AD-231A+AD-231B+AD-231C)
- Where
- South Korea
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Hyperlipidemias, Hypertension
Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072
The purpose of this study is to evaluate the Pharmacokinetic Interaction Between AD-2071 and AD-2072 in healthy male volunteers.
- Trial name
- NCT03632668
- Testing
- AD-2071 10/20mg, AD-2072 80/5mg, AD-2071 10/20mg + AD2072 80/5mg
- Where
- South Korea
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Hypertension, Hyperlipidemia
A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin
An open-label, randomized, single-dose, 2X3X3 partial replicate, crossover study to compare the pharmacokinetics and safety between a fixed dose combination of Fimasartan/Amlodipine/Rosuvastatin and Co-administration of a fixed…
- Trial name
- NCT02995720
- Testing
- Fimasartan/Amlodipine combination drug, Rosuvastatin
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd